Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Multiple myeloma gammopathies

Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma?

Leukemia volume 33, pages 588–596 (2019)Cite this article

Subjects

Abstract

Three randomized controlled trials and a meta-analysis reported lenalidomide given after high-dose therapy and an autologous hemopoietic cell transplantation is associated with increase in progression-free survival (PFS) and survival in persons with plasma cell myeloma (PCM). Based on these data, posttransplant lenalidomide is considered by many a standard-of-care in this setting. However, decisions on the use of new therapies should consider not only results of such trials and meta-analyses but also other factors including quality-of-evidence, anticipated desired and undesired effects of the drug, costs and feasibility of the therapy option. In this review, we critically analyzed evidence on posttransplant lenalidomide in PCM, and we identified criteria which should be considered in designating posttransplant lenalidomide the standard-of-care. Using Grading of Evidence, Assessment, Development and Evaluation (GRADE) approach we judged posttransplant lenalidomide improves PFS with high-quality evidence. However, we identified inconsistency and imprecision as limitations in the conclusions regarding a survival benefit rating the quality-of-evidence for a survival benefit moderate. We also highlighted inconsistency in claims of an increased risk of new cancers associated with posttransplant lenalidomide. We emphasize the need for a value-based reasoning which considers PFS and survival as well as health-related quality-of-life and costs. We conclude the decision to use posttransplant lenalidomide should be individualized based on pre- and posttransplant variables such as remission state, risk category and/or posttransplant measurable residual disease (MRD)-test results. Validity of these variables in estimating benefits and risks of posttransplant lenalidomide should be tested in randomized clinical trials.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Similar content being viewed by others

References

  1. Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116:679–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996;335:91–97.

    Article  CAS  PubMed  Google Scholar 

  3. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood. 2000;95:7–11.

    CAS  PubMed  Google Scholar 

  4. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–83.

    Article  CAS  PubMed  Google Scholar 

  5. Kumar L, Boya RR, Pai R, Harish P, Mookerjee A, Sainath B, et al. Autologous stem cell transplantation for multiple myeloma: long-term results. Natl Med J India. 2016;29:192–9.

    PubMed  Google Scholar 

  6. Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, IFM 2009 Study. et al. Lenalidomide, Bortezomib, and Dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Thoennissen GB, Görlich D, Bacher U, Aufenberg T, Hüsken AC, Hansmeier AA, et al. Autologous stem cell transplantation in multiple myeloma in the era of novel drug induction: a retrospective single-center analysis. Acta Haematol. 2017;137:163–72.

    Article  CAS  PubMed  Google Scholar 

  8. Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. J Clin Oncol. 2014;32:2712–7.

    Article  CAS  PubMed  Google Scholar 

  9. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782–91.

    Article  CAS  PubMed  Google Scholar 

  10. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:895–905.

    Article  PubMed  CAS  Google Scholar 

  12. Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91:719–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, et al. Multiple myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15:230–69.

    Article  PubMed  Google Scholar 

  14. McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv52–iv61.

    Article  CAS  PubMed  Google Scholar 

  16. Mikhael JR. Maintenance lenalidomide After transplantation in multiple myeloma prolongs survival-in most. J Clin Oncol. 2017;35:3269–71.

    Article  CAS  PubMed  Google Scholar 

  17. Kumar SK. Management of multiple myeloma. J Natl Compr Canc Netw. 2018;16(5S):624–7.

    Article  PubMed  Google Scholar 

  18. Alonso-Coello P, Schünemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016;353:i2016.

    Article  PubMed  Google Scholar 

  19. Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: clinical practice guidelines. BMJ. 2016;353:i2089.

    Article  PubMed  Google Scholar 

  20. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64:380–2.

    Article  PubMed  Google Scholar 

  21. Higgins JP, Green S (editors). Cochrane Handbook for Sysystematic Reviews of Interventions. Version 5.1.0. The Cochrane Collaboration 2011.

  22. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). J Clin Epidemiol. 2011;64:407–15.

    Article  PubMed  Google Scholar 

  23. Nielsen LK, Jarden M, Andersen CL, Frederiksen H, Abildgaard N. A systematic review of health-related quality of life in longitudinal studies of myeloma patients. Eur J Haematol. 2017;99:3–17.

    Article  PubMed  Google Scholar 

  24. European Medicines Agency. Guideline on the evaluation of anticancer medicinal products in man (13 December 2012). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/01/WC500137128.pdf. (Accessed on 6 July 2017).

  25. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol. 2011;64:1283–93.

    Article  PubMed  Google Scholar 

  26. Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014;15:333–42.

    Article  CAS  PubMed  Google Scholar 

  27. Jones JR, Cairns DA, Gregory WM, Collett C, Pawlyn C, Sigsworth R, et al. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J. 2016;6:e506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Rollison DE, Komrokji R, Lee JH, Hampras S, Fulp W, Fisher K, et al. Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide. Leuk Lymphoma. 2017;58:560–8.

    Article  CAS  PubMed  Google Scholar 

  29. Kotchetkov R, Masih-Khan E, Chu CM, Atenafu EG, Chen C, Kukreti V, et al. Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients. Cancer Med. 2017;6:3–11.

    Article  CAS  PubMed  Google Scholar 

  30. Rifkin RM, Abonour R, Shah JJ, Mehta J, Narang M, Terebelo H, et al. Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide. Leuk Lymphoma. 2016;57:2228–31.

    Article  PubMed  Google Scholar 

  31. Kahlon PS, Kuriakose P, Peres EM, Sandhu NK. Lenalidomide maintenance therapy after autologous peripheral blood stem cell transplant (PBSCT) in multiple myeloma patients: factors that impact treatment. Blood. 2017;130(Suppl_1):5416.

    Google Scholar 

  32. Smith TJ, Hillner BE. Explaining marginal benefits to patients, when “marginal” means additional but not necessarily small. Clin Cancer Res. 2010;16:5981–6.

    Article  PubMed  Google Scholar 

  33. Sobrero AF, Pastorino A, Sargent DJ, Bruzzi P. Raising the bar for antineoplastic agents: how to choose threshold values for superiority trials in advanced solid tumors. Clin Cancer Res. 2015;21:1036–43.

    Article  CAS  PubMed  Google Scholar 

  34. Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol. 2017;28:2901–5.

    Article  CAS  PubMed  Google Scholar 

  35. Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014;32:1277–80.

    Article  PubMed  Google Scholar 

  36. Verelst SG, Termorshuizen F, Uyl-de Groot CA, Schaafsma MR, Ammerlaan AH, Wittebol S, et al. Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. Ann Hematol. 2011;90:1427–39.

    Article  CAS  PubMed  Google Scholar 

  37. Sonneveld P, Verelst SG, Lewis P, Gray-Schopfer V, Hutchings A, Nixon A, et al. Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia. 2013;27:1959–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Stewart AK, Trudel S, Bahlis NJ, White D, Sabry W, Belch A, et al. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood. 2013;121:1517–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Tay J, Vij R, Norkin M, Kumar SK, Kindwall-Keller TL, Roberts JS, et al. Impact of active maintenance treatment (MT) compared to No MT on the Quality of Life (QoL) of patients with multiple myeloma (MM) following first autologous stem cell transplant (ASCT). Blood. 2017;130(Suppl_1):2150.

    Google Scholar 

  40. Chen Y, Lairson DR, Chan W, Huo J, Du XL. Cost-effectiveness of novel agents in medicare patients with multiple myeloma: findings from a U.S. Payer’s Perspective. J Manag Care Spec Pharm. 2017;23:831–43.

    PubMed  Google Scholar 

  41. Kim MY, Sposto R, Swaika A, Asano H, Alamgir A, Chanan-Khan A et al. Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma. Oncology. 2014;87:224–31.

    Article  CAS  PubMed  Google Scholar 

  42. Rajkumar SV, Harousseau JL. Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. Blood. 2016;128:2757–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Jackson G, Dutton R, Zamagni E, Hughes R, Dhanasiri S. Lenalidomide maintenance therapy post-autologous stem cell transplant: a healthcare cost-impact analysis in Europe. Blood. 2017;130(Suppl_1):3405.

    Google Scholar 

  44. Hari P, Ung B, Abouzaid S, Ni Q, Parikh K, Agarwal A. Lenalidomide maintenance for patients with newly diagnosed multiple myeloma post autologous stem cell transplant: a comparison of real-world treatment outcomes and costs. Blood. 2017;130(Suppl_1):2189.

    Google Scholar 

  45. Brown RE, Stern S, Dhanasiri S, Schey S. Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales. Eur J Health Econ. 2013;14:507–14.

    Article  PubMed  Google Scholar 

  46. Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012;119:2100–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J. 2015;5:e365.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Solovev MV, Mendeleeva LP, Pokrovskaya OS, Gemdzhian EG, Kuzmina LA, Firsova MV, et al. The Duration of MRD-negative status in multiple myeloma (MM) patients after auto-HSCT is a criterion for prolonged remission without maintenance therapy. Blood. 2017;130(Suppl_1):3294.

    Google Scholar 

  49. Goldschmidt H, Mai EK, Dürig J, Scheid C, Weisel KC, Kunz C, et al. Response-adapted lenalidomide maintenance in newly diagnosed, transplant-eligible multiple myeloma: results from the multicenter phase III GMMG-MM5 trial. Blood. 2017;130(Suppl_1):400.

    Google Scholar 

  50. Jackson G, Davies FE, Pawlyn C, Cairns D, Striha A, Hockaday A, et al. Lenalidomide maintenance significantly improves outcomes compared to observation irrespective of cytogenetic risk: results of the myeloma XI trial. Blood. 2017;130(Suppl_1):436.

    Google Scholar 

Download references

Acknowledgements

We are responsible for the views expressed and do not represent the views, decisions, or policies of the institutions with which they are affiliated. Prof. Mohammed Hussein (Univ. South Florida and Celgene Corp.) kindly reviewed the typescript and made helpful suggestions.

Author information

Authors and Affiliations

  1. Center for the Study of Myelofibrosis, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy

    Giovanni Barosi

  2. Haematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College, London, UK

    Robert Peter Gale

Authors
  1. Giovanni Barosi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Peter Gale
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Barosi.

Ethics declarations

Conflict of interest

GB received advisory board funds from Novartis. RPG is a part-time employee of Celgene Corp.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barosi, G., Gale, R.P. Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma?. Leukemia 33, 588–596 (2019). https://doi.org/10.1038/s41375-019-0383-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-019-0383-2

This article is cited by

Search

Advanced search

Quick links